Results 231 to 240 of about 152,115 (284)

The Conjugation of Antibodies to Heat Shock Protein 70 Activates Immune Responses Against Tumor Cells. [PDF]

Immunotargets Ther
Khosravi M, Rajaei A, Mohammadian B, Seyfi Abad Shapouri M.   +3 more
europepmc   +1 more source

Design, Synthesis and Evaluation of Anticancer Potential of Novel Pyrrolopyrazines Against Glioblastoma: Mechanistic Details and In Vivo Safety Analysis

Archiv der Pharmazie, Volume 359, Issue 4, April 2026.
Propargyl–pyrrole cyclization yielded 12 pyrrolo[1,2‐a]pyrazine derivatives, with naphthyl‐substituted 3g showing potent antiproliferative activity against U87MG glioblastoma. Compound 3g induced multiple cell death pathways without significant renal or hepatic toxicity, highlighting its promise as a glioblastoma therapeutic candidate.
Ayşe Usta, Burak Kuzu, Meltem Tan‐Uygun, Veysel Yüksek, M. Edip Akyol, Nurettin Menges   +5 more
wiley   +1 more source

Intralesional bevacizumab as an adjuvant approach to recurrent respiratory papillomatosis: A prospective study on different treatment protocols. [PDF]

PLoS One
Klimza H, Zakrzewski B, Porębski A, Wierzbicka M.   +3 more
europepmc   +1 more source

Combining Small‐Molecular Compounds With CAR T‐Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy

Cancer Innovation, Volume 5, Issue 2, April 2026.
Chimeric antigen receptor (CAR) T‐cell therapy, although revolutionary for haematological malignancies, faces significant challenges, including T‐cell exhaustion, limited persistence, and treatment‐related toxicity. The integration of small‐molecule compounds offers a promising strategy to overcome these limitations.
Rangzi Yi, Zijian Zhang, Yang Yang, Haichuan Zhu   +3 more
wiley   +1 more source

The Effect of Bevacizumab Therapy on Reducing Erythrocyte Transfusion Requirements and Preventing Iron Deficiency in Patients With Hereditary Hemorrhagic Telangiectasia. [PDF]

Cureus
Aydın Ö, Köseoğlu FD, Sayın S, Gözden HE, Şahin O, Ataş Ü, Kürekci DD, Aktimur SH, Aylı M, Turgut M, Güven S.   +10 more
europepmc   +1 more source

Annual Review of Systemic Medical Treatment for Colorectal Cancer in 2025

Cancer Innovation, Volume 5, Issue 2, April 2026.
Tissue biopsy and molecular profilingenable precise patient stratification into distinct molecular subtypes, which guides the selection of precision treatment. Furthermore, longitudinal liquid biopsies facilitate serial ctDNA monitoring for MRD detection and continuous surveillance.
Zengzhi Cai, Fan Chen, Ying Jin, Feng Wang   +3 more
wiley   +1 more source

Antiangiogenic therapy for advanced biliary tract cancers: promising or illusory? [PDF]

J Gastrointest Oncol
Colle R, Malka D.
europepmc   +1 more source

Global Advances in Hepatocellular Carcinoma Research and Therapy in 2025

Cancer Innovation, Volume 5, Issue 2, April 2026.
This review summarizes key breakthrough advances in hepatocellular carcinoma (HCC) reported in 2025 and presents a multidisciplinary management framework for HCC, integrating early diagnosis, microenvironment insights, and comprehensive therapeutic strategies spanning minimally invasive surgery, locoregional interventions, and systemic pharmacotherapy.
Bo Hu, Qiang Gao
wiley   +1 more source

Rethinking maintenance strategies in biliary tract cancers. [PDF]

Transl Gastroenterol Hepatol
Grewal US, Brown TJ.
europepmc   +1 more source

Analysis on the efficacy and safety of chemotherapy combined with or without bevacizumab after CRS+HIPEC in patients with malignant peritoneal mesothelioma: a single-center retrospective study. [PDF]

Front Oncol
Yang ZR, Liang XL, Li XB, Zhang XJ, Wu HL, Su YD, Li Y, An SL.   +7 more
europepmc   +1 more source